PUR — Pure Biologics SA Balance Sheet
0.000.00%
- PLN26.10m
- PLN40.37m
Annual balance sheet for Pure Biologics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | PAS | PAS | PAS | PAS | PAS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8.96 | 32.9 | 7.18 | 3.61 | 0.313 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.35 | 9.29 | 15.2 | 14.7 | 1.67 | 
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13 | 43 | 24.2 | 18.8 | 2.09 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.88 | 3.45 | 8.42 | 0.881 | 0.12 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 18.9 | 47.2 | 33 | 22.7 | 2.34 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18 | 5.55 | 12.8 | 7.21 | 15.4 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 21.8 | 7.7 | 14.7 | 20.8 | 15.5 | 
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.89 | 39.5 | 18.3 | 1.89 | -13.1 | 
| Total Liabilities & Shareholders' Equity | 18.9 | 47.2 | 33 | 22.7 | 2.34 | 
| Total Common Shares Outstanding |